The Latest
Insight
Competition EO Opens Door to Antitrust Enforcement and the Public Option
Weekly Checkup
The Return of H.R. 3
Insight
Prescription Drug Price Controls and State-Level Policymaking
Weekly Checkup
Two Lost Opportunities for Bipartisan Legislating
Insight
Comparing the Recent Drug-Pricing Reform Proposals
Weekly Checkup
Don’t Believe Everything You Read in CBO Cost Estimates
Insight
Competing Proposals to Reform Medicare Part D
Testimony
Testimony on The Lower Drug Costs Now Act (H.R. 3)
Weekly Checkup
Negotiation in Speaker Pelosi’s Drug-Pricing Proposal
Weekly Checkup
Competition and Pelosi’s Prescription Drug Plan
Insight
Senate Finance Proposes Reforms to Medicare and Medicaid Drug Policy
Weekly Checkup
The Sound and Fury on Drug Importation
Insight
How Congress Is Attempting to Lower Drug Costs
Background Research
Multimedia
The Effect of H.R. 3 on Drug Prices and Innovation
AAF’s Director of Health Care Policy Christopher Holt explains why Democrats’ proposed drug-pricing legislation, H.R. 3, will restrict drug availability and innovation.
Multimedia
Prescription Drug Prices
AAF’s Director of Health Care Policy Christopher Holt explains why the state-level efforts to import foreign price-control regimes are not the solution to high prescription drug prices.
Insight
Obstacles to Success of the Drug Importation Plan
Insight
The Challenges Facing the Trump Administration’s Drug Importation Plan
Weekly Checkup
The Problems with Trump’s Expected Drug-Policy Rules
Weekly Checkup
Drug-Pricing Reform and the CARES Act
Research
Understanding Pharmaceutical Drug Costs
Insight
Understanding the Policies that Influence the Cost of Drugs
Insight
Baseball, Arbitration, and Drug Prices
Testimony
Testimony Before the Senate Committee on Finance on Drug Pricing
Weekly Checkup
The Importance of Investment Incentives in Drug Pricing Policies
Weekly Checkup
Importing Canadian Drugs is Not the Solution to High Drug Prices
Multimedia
The AAF Exchange — Ep. 04: Drug Pricing in the U.S.
AAF’s Director of Health Care Policy Chris Holt discusses the issue of high drug prices as well as several proposed solutions for it.
Medicare Part D
Testimony
Lower Drug Costs Now: Expanding Access to Affordable Health Care
Weekly Checkup
An Opportunity for Bipartisan Drug-Pricing Reform
Insight
The Drug Rebate Rule: What’s the Budget Impact?
Research
Redesigning Medicare Part D to Realign Incentives
Insight
UPDATE: The Many Competing Proposals to Reform Medicare Part D
Insight
Analysis of the Competing Proposals to Reform Medicare Part D
Insight
Comparing the Recent Drug-Pricing Reform Proposals
Insight
The Impact of Shifting Rebates to Catastrophic Coverage in Medicare Part D
Weekly Checkup
Where Does It Go From Here? Drug Pricing Policy After the Rebate Rule Reversal
Insight
What Congress Needs to Consider When Reforming Medicare Part D
Multimedia
The AAF Exchange — Ep. 09: Drug Pricing Reform
Deputy Director of Health Care Policy Tara O'Neill Hayes walks listeners through the latest reform efforts in drug pricing.
Senate Finance Proposes Reforms to Medicare and Medicaid Drug Policy
Medicare Part B
Insight
The Impact of a Most Favored Nation Drug Price Rulemaking on Innovation
Weekly Checkup
It’s Back! The International Price Index Rears Its Ugly Head
Weekly Checkup
Inconsistency and Hypocrisy on an International Price Index
Comments for the Record
Comments To CMS On Proposed International Pricing Index for Medicare Part B Drugs
Weekly Checkup
Importing Drug Price Controls
Insight
Comparing the Recent Drug-Pricing Reform Proposals
Medicaid
Research
Primer: The Medicaid Drug Rebate Program
Weekly Checkup
Laboratories of Drug Pricing Policy
Insight
Comparing the Recent Drug-Pricing Reform Proposals
340B
Weekly Checkup
340B and the Biden Administration
Insight
CMS Moves Toward Much-Needed 340B Reforms
Insight
Assessing the Administration’s Proposal for Reducing Insulin and Epinephrine Costs
Research
Market Distortions Caused by the 340B Prescription Drug Program
Weekly Checkup
It’s Back! The International Price Index Rears Its Ugly Head
Weekly Checkup
“Let 340B” Jumps the Shark
Insight
Reforming 340B
The 340B drug pricing program requires pharmaceutical manufacturers to provide outpatient medications at steeply discounted prices to certain types of hospitals and health clinics. Intended to provide critical cost savings for hospitals and other entities that provide charitable care for patients without health coverage, eligibility for the largest proportion of entities participating in the program is based on a funding formula that relies on the proportion of Medicare and Medicaid inpatients served by a given hospital. As 340B enters its third decade as part of the federal health funding structure, now is a good time to reevaluate and make sure it is working as intended. This short paper argues that a fundamental change in the formula would better reflect the program’s stated priority.
Research
Primer: Understanding the 340B Drug Pricing Program
The 340B program was originally intended to correct an imbalance created by the passage of the Medicaid Drug Rebate statute. It was meant to play only a small role in the health insurance market. However, as with most interferences in the free-market, the 340B rule has “expanded beyond its bounds”, in the words of outgoing Secretary of HHS Kathleen Sebelius. As the program has expanded the market inefficiencies it created have been magnified.